Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Mar 3;94(9):e884-e896.
doi: 10.1212/WNL.0000000000009035. Epub 2020 Feb 11.

A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores

Collaborators, Affiliations
Multicenter Study

A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores

Vera Fridman et al. Neurology. .

Abstract

Objective: To evaluate the sensitivity of Rasch analysis-based, weighted Charcot-Marie-Tooth Neuropathy and Examination Scores (CMTNS-R and CMTES-R) to clinical progression in patients with Charcot-Marie-Tooth disease type 1A (CMT1A).

Methods: Patients with CMT1A from 18 sites of the Inherited Neuropathies Consortium were evaluated between 2009 and 2018. Weighted CMTNS and CMTES modified category responses were developed with Rasch analysis of the standard scores. Change from baseline for CMTNS-R and CMTES-R was estimated with longitudinal regression models.

Results: Baseline CMTNS-R and CMTES-R scores were available for 517 and 1,177 participants, respectively. Mean ± SD age of participants with available CMTES-R scores was 41 ± 18 (range 4-87) years, and 56% were female. Follow-up CMTES-R assessments at 1, 2, and 3 years were available for 377, 321, and 244 patients. A mixed regression model showed significant change in CMTES-R score at years 2 through 6 compared to baseline (mean change from baseline 0.59 points at 2 years, p = 0.0004, n = 321). Compared to the original CMTES, the CMTES-R revealed a 55% improvement in the standardized response mean (mean change/SD change) at 2 years (0.17 vs 0.11). Change in CMTES-R at 2 years was greatest in mildly to moderately affected patients (1.48-point mean change, 95% confidence interval 0.99-1.97, p < 0.0001, for baseline CMTES-R score 0-9).

Conclusion: The CMTES-R demonstrates change over time in patients with CMT1A and is more sensitive than the original CMTES. The CMTES-R was most sensitive to change in patients with mild to moderate baseline disease severity and failed to capture progression in patients with severe CMT1A.

Clinicaltrialsgov identifier: NCT01193075.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Change in CMTES-R score over 6 years
Change in Rasch analysis-adjusted Charcot-Marie-Tooth Examination Scores (CMTES-R) from baseline over a 6-year period. CMTES-R scores increase gradually over subsequent years with relatively linear progression. Linear model estimates a change in mean CMTES-R score of 0.59 (95% confidence interval [CI] 0.44–0.74, p < 0.0001) over 2 years.
Figure 2
Figure 2. Change in CMTES score over 6 years
Change in Charcot-Marie-Tooth Examination Score (CMTES) from baseline over a 6-year period. CMTES scores increase gradually over subsequent years with relatively linear progression. CI = confidence interval.
Figure 3
Figure 3. Influence of baseline disease severity on change in CMTES-R score (mixed model regression)
Categorical model showing change in Rasch-modified Charcot-Marie-Tooth Examination Score (CMTES-R) based on disease severity at baseline over a 6-year period. Red indicates mild (CMTES-R score 0–9); green, moderate (CMTES-R score 10–18); and blue, severe (CMTES-R score >19). Bars are 95% confidence intervals (CIs). Mildly and moderately affected patients show more disease progression than severely affected patients. SRM = standardized response mean.
Figure 4
Figure 4. Change in CMTNS-R score over 4 years
Categorical model showing change in Rasch-modified Charcot-Marie-Tooth Examination Scores (CMTNS-R) from baseline over a 4-year period. CMTNS-R scores increase over subsequent years.
Figure 5
Figure 5. Responsiveness to change of individual CMTES items at 2 years
Change in individual Charcot-Marie-Tooth Examination Score (CMTES) items over a 2-year period. Pinprick sensibility and arm strength were least responsive.

Comment in

References

    1. Reilly MM, Murphy SM, Laura M. Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011;16:1–14. - PubMed
    1. Juneja M, Burns J, Saporta MA, Timmerman V. Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development. J Neurol Neurosurg Psychiatry 2019;90:58–67. - PMC - PubMed
    1. Shy ME, Blake J, Krajewski K, et al. . Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005;64:1209–1214. - PubMed
    1. Lewis RA, McDermott MP, Herrmann DN, et al. . High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 2013;70:981–987. - PMC - PubMed
    1. Pareyson D, Reilly MM, Schenone A, et al. . Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011;10:320–328. - PMC - PubMed

Publication types

Associated data